Palo Alto Investors’s Novavax NVAX Stock Holding History

Palo Alto Investors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,500	Closed	-$643K	–	33
2022 Q2	$643K	Hold	12,500	–	–	0.06%	28
2022 Q1	$921K	Hold	12,500	–	–	0.07%	30
2021 Q4	$1.79M	Buy	+12,500	New	+$2.15M	0.11%	28

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Palo Alto Investors's NVAX Position: Q3 2022 in Review

Palo Alto Investors sold out of Novavax (NVAX) in Q3 2022, closing a stake of 12,500 shares — an estimated $643K sold.

Palo Alto Investors first reported a position in NVAX in Q4 2021 and held it in 3 quarters. The position peaked at $1.79M in Q4 2021. 254 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Palo Alto Investors reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Palo Alto Investors sold 12,500 Novavax shares in Q3 2022, an estimated $643K.
Palo Alto Investors first reported a position in Novavax in Q4 2021 and held it in 3 quarters.
Palo Alto Investors's Novavax position peaked at $1.79M in Q4 2021.
254 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Palo Alto Investors's 13F filing for Q3 2022, filed 14 Nov 2022.